anonymous
Guest
anonymous
Guest
Investors have lost faith in the management's abilities to transform Shire into a biotech specialized in "Orphan Diseases," as a result of a massive negative earnings revision seen in 2017.
https://seekingalpha.com/article/4134638-went-wrong-shire-2017-2018-will-different
Why will 2018 be different?
https://seekingalpha.com/article/4134638-went-wrong-shire-2017-2018-will-different
Why will 2018 be different?